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In some animal species, exposure of the ocular lens to 
8-methoxypsoralen (8-MOP) and ultraviolet-A radia-
tion (PUV A) induces lens opacities. Case reports have 
suggested that PUV A therapy in humans may be asso-
ciated with an increased risk of ocular lens abnormali-
ties. To examine this risk, we compared the results of 
the initial and final examinations, which were per-
formed on an average of 10 years apart in 1,235 indi-
viduals enrolled in the PUV A Follow-up Study. 
After adjustment for age and sex, there was no sig-
nificant relation between the risk of developing an oc-
ular lens abnormality or cataract and the level of expo-
sure to PUV A. A higher incidence of cataract was 
noted, however, in the PUV A cohort compared to a 
large population-based study. In addition, rates of cat-
Since 1974, when the efficacy of oral psoralen photoche-motherapy (PUV A) for the treatment of psoriasis was first described, more than 100,000 persons have used this treatment [1] . A substantial proportion of these individu-als have .used PUV A therapy for many years, and some 
have been exposed to hundreds of treatments. The PUV A Follow-
up Study is a 16-center prospective cohort study of 1380 people 
with psoriasis who first received PUV A treatment in 1975 -1976. 
Since 1975, the study has assessed the safety and efficacy ofPUVA 
[2]. 
After oral administration, psoralens are found in human and ani-
mal lenses [3 - 5]. With exposure to ultraviolet (UV)A, psoralens 
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aract extraction were significantly higher among male 
members of the PUV A study compared to enrollees in 
the Physician Health Study. 
Overall, our data strongly argue against a dose-de-
pendent increase in the risk of cataract or other lens 
abnormality in association with PUV A therapy in a 
cohort most of whose members we believe usually used 
recommended eye protection. Our data do not explain 
the higher incidence and prevalence of ocular lens pa-
thology in our cohort compared to groups without 
psoriasis. These differences could reflect differences in 
criteria for defining these abnormalities, other expo-
sures, or PUV A. Key words: Psoriasis /PUV A therapy / cat-
aract/ocular lens.] Invest DermatoI103:534-538, 1994 
photobind to lens proteins [6] . In some animal species ocular expo-
sure to psoralens and UV A accelerates the development of ocular 
lens opacities, but in other species this does not appear to be a 
problem [6-9]. Because of concerns about this and other potential 
ocular toxicities associated with PUVA therapy, patients enrolled 
in this PUV A study have been advised to use UV A blocking lenses 
for at least 12 h following psoralen ingestion whenever they are 
exposed to UV A from the sun or artificial light sources. The official 
labeling of the drug calls for use of ocular protection for 24 h [10]. 
Assessing the ocular risk associated with exposure to PUV A is one 
of the primary goals of the PUVA Follow-up Study. After 5 years, 
no significant dose-dependent increase in the risk of developing 
symptomatic cataracts was noted in members of this cohort [11] . A 
small increase in the risk of developing nuclear sclerosis and poste-
rior subcapsular opacities among patients who received at least 100 
PUVA treatments compared to patients with fewer than 100 treat-
ments was, however, noted [11]. In this report, we present an analy-
sis of ocular findings, especially lens changes, which reflect a decade 
of prospective study of this cohort. 
MATERIALS AND METHODS 
In this study, we included all people in the PUV A cohort who had received 
at least two ophthalmologic examinations utilizing either of two compre-
hensive ophthalmologic examination forms designed for this study. The 
first was used from 1975 to 1986. This structured examination form 
recorded best corrected visual acuity and the presence or absence of specific 
ocular abnormalities, including lens abnormalities. If a lens abnormality was 
noted, the examining physician was instructed to "through dilated pupils 
note corticonuclear, posterior subcapsular, or other significant cataracts ex-
cluding flecks." The examiner was also asked to note in free text fonnat the 
extent and location of any such opacities. The second revised ophthalmo-
logic eye examination form has been utilized since 1986. This form also 
provides a stmctured format to record visual acuity, the presence of lens 
abnormalities, aphakia, or an intraocular lens. If a lens abnormality was 
0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 
534 
VOL. 103, NO.4 OCTOBER 1994 
Table I. Prevalence (%) of Any Lens Abnormalities 
Except Flecks and Vacuoles at First and Last Examination 
and Incidence by Age at Midpoint of Study 
Prevalence 
Age n Initial Final Incidence" 
<45 495 8.9% 11 .3% 2.5 
45-54 259 12.0% 25.5% 13.9 
55-64 280 25.7% 45.7% 20.5 
~65 201 38.8% 70.1% 34.4 
All 
ages 1235 18.2% 31.7% 13.8 
" Per 1000 person-years of follow-up. 
noted, the examiner was instructed to record whether the lens abnormality 
consists only of flecks or vacuoles only, or any other abnormalities. If any 
lens abnormality other than flecks or vacuoles is noted, the examiner is asked 
to determine whether the decreased lucency is located in the nucleus or in 
the posterior subcapsular area of the lens. If lenticul ar changes are noted 
and a patient has a best correct visual acuity of20 /30 or worse in that eye, the 
examiner is asked to assess whether this abnormal visua.l acuity is attributable 
to the lens abnormalities. Ophthalmologists performed most examinations, 
but examinations performed by Doctors of Optometry were also accepted. 
Study Population All 1380 patients who were first treated with PUVA 
from 1975 - 1976 at 16 university centers were eligible for entry into our 
prospective follow-up study. Of these 1380 patients, 1299 (94%) had initial 
examinations recorded on the first structured eye examination form. Of 
these 1299 patients, 1235 (95%) had at least two complete examinations 
recorded on these structured forms. These 1235 patients are the study popu-
lation for this report. These 1235 patients were, on average, 43 years old at 
entry into the study and 64% were male, not significantly different from the 
proportion of males for whom at least two eye examinations were unavai l-
able (p > 0.05). These 1235 patients form the study populations for this 
report. The 143 patients in the cohort for whom we did not have two eye 
forms completed and who are excluded from this report were notable for 
their older average age at entry (p < 0.005) and significantly lower average 
number of PUVA treatments (p < 0.001) The methodology of the study 
and the characteristics of the cohort have been detailed previously [2,11]. 
End Points We defined as our primary endpoints for this study the occur-
rence in either eye of a lens abnormality other than flecks or vacnoles, which 
we define as a lens abnormality. We also determined the prevalence of 
people with decreased nuclear lucency or posterior subcapsular lens abnor-
malities. We also determined the increase in the number of prevalent cases of 
each abnormality in our study group (i.e., the difference in the prevalence of 
those with an abnormality on final examination compared to the prevalence 
on first examination). We examined the rclation of PUVA dose to the 
development oflens abnormalities (other than flecks and vacuoles) alone and 
when this abnormality was observed with a best corrected visual acuity of 
20/30 or worse, which is the definition of cataract used in our study. 
We define low-dose exposure to PUV A to be less than 140 treatments as 
recorded an average of 10 years after first treatment. A medium dose of 
PUV A is defined as 140 - 239 treatments, and high-dose exposure to PUV A 
is defined as exposure to more than 239 treatments. Relative levels at PUVA 
follow-up interview 10 years after first treatment were highly correlated 
Table II. Prevalence of Cataracts (Persons) at First and 
Final Examination and Incidence of Cataracts by Age at 
Midpoint of Study 
Prevalence (Percent) 
Age n Initial Exam Final Exam Incidence" 
<45 495 0.4 1.2 0.8 
45-54 259 1.5 10.4 9. 1 
55-64 280 6.1 22.1 16.5 
2:65 201 20.9 58.2 41.0 
All 
ages 1235 5.3 17.2 12.3 
• Per 1000 person-years of follow-up. 
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Table m. Comparisons of Prevalence (%) of Nuclear 
Opacities and Posterior Subcapsular Opacities in the 
Beaver Dam study and the PUV A Study by Age 
Posterior Subcapsular 
Nuclear Opacities" Opacitiesb 
Age Beaver Dam' PUVA Beaver Dam' PUVA 
30-39 0% 2.7% 1.0% 3.7% 
40-49 4.1% 4.7% 0% 6.4% 
50-59 13.9% 16.7% 1.8% 6.8% 
60-69 47.7% 32.1% 3.4% 11.1% 
70-79 78.1 % 45.5% 2.8% 14.7% 
2:80 66.7% 51.4% 0% 8.6% 
, Age-standardized prevalence higher in Beaver Dam than PUVA (p < 0.05). 
• Age-standardized prevalence higher in PUV A than Beaver Dam (p < 0.05). 
' Data from (13). 
with exposure levels noted on earl ier interviews (R = 0.58-0.87, P < 0.001 
all correlations). 
For each endpoint, we related level of exposure to PUVA at the time of 
their follow-up interview, completed an average of 10 years after fi.rst PUV A 
treatment, to the odds of developing a specific lens abnormality with or 
without visual impairment. We also compared the age-specific prevalence of 
abnormal visual acuity and lens abnormalities as recorded at final examina-
tion with the occurrence of various types of eye pathology noted in three 
population-based studies, the Beaver Dam Study, the Framingham Eye 
Study, and the Physicians Health Study (cataract extraction in men only) 
[1 2-15]. 
Statistical Methods We first performed univariate analyses to determine 
the relation of patients' attributes and exposures to the risk of developing a 
specific ocular abnormality. We tben used logistic regression to test whether 
patient attributes and level of exposu.re to PUVA were related to the risk of 
developing specific ocular abnormalities after adjustment for age and sex. 
For factors with more than two groups, we constructed dummy variables 
(14). To control for risk factors including age and sex, which might covary 
with level of exposure to PUVA, we specified multivariate models, which 
included these three variables (and their dummy variables). The coefficients 
from those models were then converted into adjusted odds ratios, and the 
95% confidence intervals were determined. We used the chi-square test to 
determine the statistical significance of differences in proportions and the t 
test to determine the statistical significance of differences in means. 
RESULTS 
The interval from first eye examination on a standardized form to 
final eye examination on a standardized form was 9.6 ± 3.7 years 
(mode = 11.6 years). For 90% of the patients there was at least 3.4 
years between initial and final eye examination, and for 82% of 
patients there was at least 5 years between first and final eye exami-
nation. 
Patients over 65 had a significantly lower mean duration of fol-
low-up (p < 0.001), and death was the most frequent reason for 
follow-up of less than 6.4 years; it accounted for 43% of patients 
with follow-up of less than 9 years. Both the incidence and preva-
lence of lens abnormalities, abnormal visual acuity, and cataract 
increased rapidly with increasing age. Table I presents the preva-
lence of lens abnormalities on the initial and final eye examinations 
by the age of patient at midpoint in the study. Table II presents the 
prevalence of cataracts (defined as a lens abnormality and a best 
corrected visual acuity of20/30 or worse) on initial and final exam-
inations. 
On initial examination, there were a total of 225 (18 %) patients 
with any lens abnormalities and a best corrected visual acuity of 
20/30 or worse in one or both eyes. On final examination, there 
were 391 (32%) such persons. Tables III and IV compare the 
prevalence of selected lens abnormalities, including cataract, for the 
PUVA study cohort on final examination with the results of the 
Beaver Dam and Framingham Studies, respectively. Table V com-
pares rates of cataract extraction by age for men enrolled in the 
PUVA cohort and the Physicians Health Study. Overall, the age-
adjusted rate of cataract extraction was more than fourfold higher 
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Table IV. Comparison of Prevalence of Nuclear Opacity, Posterior Subcapsular Opacity, and Cataract: Framingham 
Versus PUV A Study by Age 
Nuclear Opacity' Posterior Subcapsular- Cataractb 
Age Framingham PUVA Framingham 
52- 64 9.7% 22.5% 3.0% 
65 - 74 32.2% 37.8% 8.2% 
> 75 60.0% 53.8% 16.5% 
• Defined as lens abnormality and best corrected visual acuity of 20/30 or worse. 
, Age-standardized prevalence higher in PUV A Study (p < 0.05). 
among the PUV A cohort compared to that for men enrolled in the 
Physicians Health Study (p < 0.05). 
Relation to Patient Attributes and Exposures The univariate 
analysis demonstrated that the odds of having a lens abnormality on 
final examination was most strongly related to age and not signifi-
cantly related to level of exposure to PUV A (Table VI). The rela-
tive risk of specific lens abnormalities other than flecks or vacuoles 
on final examination, based on our multivariate logistic model, is 
presented in Table VII. As noted in Table VII, the risk of any lens 
abnormality, a nuclear opacity, and a posterior subcapsular opacity 
all increased markedly with age. In this multivariate model, there is 
no significant relation between level of exposure to PUV A and the 
risk of any of four types of lens abnormalities we examined. A 
logistic model that restricted the analysis to patients with normal 
lenses on initial examination gave similar results as those displayed 
in Table VII and did not demonstrate any significant relationship 
between dose level ofPUVA and the risk of developing any of these 
four abnormalities (p > 0.05, all comparisons) . 
DISCUSSION 
Based on ophthafmologic examinations performed utilizing two 
standardized forms, we have documented the initial and final preva-
lence of ocular abnormalities in members of the PUVA Follow-up 
Study, a large cohort of patients with psoriasis who were initially 
treated at 16 university centers in 1975 -1976 [11,16]. Our current 
study, which spans 10 years, does not demonstrate any significant 
relation between the relative level of exposure to PUV A and the risk 
of cataract at the time of final examination. These findings are 
consistent with our findings after 5 years [11]. In contrast to our 
earlie~ findings that showed a slightly higher risk for the occurrence 
of nuclear sclerosis or posterior subcapsular opacity among patients 
exposed to higher doses of PUVA, after adjustment for age and sex, 
our current data do not demonstrate any significant relation of the 
risk of either of these abnormalities to the level of exposure to 
PUV A. An additional analysis restricted to individuals with normal 
visual acuity and normal lenses at first exatnination also failed to 
demonstrate any significant relation between level of exposure to 
PUV A and the lens abnorma lities we studied. These data suggest 
that prolonged exposure to PUV A with recommended eye protec-
tion, such as we believe has been practiced by most members of our 
cohort, is unlikely to result in a dose-dependent increase in the risk 
of clinically important ocular lens changes. 
We compared the final age-specific prevalence of a number of 
Table V. Rates of Cataract Extraction (Persons) per 
10,000 Person-Years by Age for PUVA Follow-Up Study 
and Physicians Health Study· (Male Only) 
Age PUVA Study Physicians Health Study 
40 - 49 34 2 
50 - 54 42 10 
60 - 69 142 23 
70 - 84 133 36 
, Age-standardized incidence higher in PUV A Study (p < 0.05). 
PUVA Framingham PUVA 
8.1 % 3.5% 13.2% 
13.0% 13.0% 39.0% 
15.0% 41.4% 62.5% 
specific lens and visual abnormalities in our cohort with that ob-
served in two United States population-based studies. The magni-
tude of the age-dependent increase in the relative risk of posterior 
subcapsular opacities was comparable in our study and the Beaver 
Dam Study, but the age-standardized prevalence of posterior sub-
capsular opacities was significantly higher in the PUVA Study [12]. 
Our second comparison group for prevalence was the Framingham 
Eye Study [13]. In comparison to this study, the prevalence of nu-
clear opacities and posterior subcapsular opacities was similar for 
patients over 65 in the PUVA and Framingham studies. For patients 
under 65, a significantly higher prevalence of both nuclear and 
posterior subcapsular opacities was noted in our study. For all age 
groups the prevalence of cataract was higher in the PUV A study 
compared to the Framingham Eye Study. As we noted previously, 
however, the Fratningham Eye Study almost certainly uses more 
stringent examination criteria for best corrected vision [11] . There-
fore, the differences in the prevalence of cataract between our study 
and the Framingham Eye Study may reflect differences in examina-
tion techniques and diagnostic criteria utilized in the two studies. 
We do, however, lack data that explain this finding directly. We 
believe that the higher prevalence of lens abnormalities in our co-
hort compared to other groups may also reflect exposures to agents 
other than PUVA (systemic corticosteroids, etc.) that nught induce 
lens changes in patients with psoriasis. A role for PUV A cannot be 
excluded. Of some concern, however, is the somewhat higher prev-
alence of cataract in patients 52 - 64 and 65 - 74 on final examina-
tion than was noted in patients of the same age enrolled in the 
PUVA cohort when examined 5 years earlier. 
The greatest discrepancy we noted between our results and the 
findings of the studies we uti lized for comparison was the fourfold 
higher rate oflens extraction in our cohort compared to that for men 
in the Physicians Health Study [14,15]. This finding concerns us, 
but we do note that cataract extraction rates in our cohort are com-
parable to hospital discharge rates for cataract among persons over 
65 but are higher than rates for those aged 45-65 [17] . Also, the 
Table VI. Odds Ratio (OR) of any Lens Abnormality or 
Cataract in Relation to Demographic Characteristics and 
Exposures (Univariate Analysis) 
Any Lens Abnormality Cataract 
OR 95% CI OR 95% CI 
Level of Exposure 
to PUVA 
High 1.20 0.89 - 1.61 0.85 0.58-1.23 
Mid 1.17 0.87 - 1.56 0.82 0.57-1.19 
Low 1 1 
Gender 
Male 1.11 0.86 - 1.43 1.07 0.78-1.45 
Female 1 1 
Age 
< 52 1 1 
52 - 64 3.83 2.72-5.40 7.37 3.77-14.42 
65 - 74 9.60 6.67-13.80 31.01 16.19 - 59.38 
~75 32.34 17.92 - 58.34 90.06 43.28 -189.88 
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Table VII. Odds Ratios for Lens Abnormality, Posterior Subcapsular Cataract, Nuclear Opacity, and Cataract by Age, 
Gender, and Level of Exposure to PUVA 
Lens Abnormality Post-Subcapsular Nuclear Opacity Cataracts 
Risk Factor OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Age 
-:275 33.3 18.4 - 60.2 3.1 1.5-6.5 34.0 
15.3 
6.8 
1 
17.7-66.6 
9.1-25.6 
4. 1 - 11.1 
90.6 43.2-190.1 
65-74 9.7 6.7 -14.0 2.7 1.6 - 4.7 32.7 17.0 -62.9 
52 -64 . 3.8 2.7-5.4 1.6 1.9 -2.8 7.7 3.9-15.1 
<52 1 1 
Gender 
Male 1.13 0.84 - 1.51 
Female 
PUVA 
High 1.27 0.91-1.77 
Mid 1.16 0.83- 1.62 
Low 1 
• Not entered into model because tolerance < 0.001 . 
socioeconomic characteristics of our cohort are far more diverse 
than those of the Physicians Health Survey. Further, an analysis 
restricted to members of the cohort 60 years of age at the midpoint 
of th e study does not reveal any significant relation between the 
level of exposure to PUVA and the risk of cataract or other lens 
abnormality. 
Case reports suggesting lenticular damage in some patients using 
PUV A therapy are a continuing source of concern, but these isolated 
findings are difficult to interpret [18 - 20). Other studies of cohorts 
of PUVA-treated patients have suggested there is littl e risk of ocular 
damage associated with the use ofPUV A, but these studies followed 
smaller cohorts often for limited periods and their powers to detect 
increased risk are generally quite low [21 -26). 
Taken together, our data strongly argue against a direct dose-de-
pendent increase in the risk of clinically relevant ocular lens abnor-
malities among patients exposed to PUV A. The higher age-specific 
prevalence of some types of lenticular pathology observed in our 
cohort compared to two population-based studies may reflect dif-
ferences in class ification of these abnormalities, examination tech-
nique, or may be the result of other exposures (i .e., corticosteroids). 
Based on our data, we cannot reject the hypothesis that exposure to 
PUV A increases the risk of lens abnormalities even though the risk 
did not increase as exposure to PUV A increased. 
Although patients are instructed to use eye protection on treat-
ment days, some patients may not regularly use eye protection. In 
the absence of adequate eye protection even low levels of exposure 
to PUVA might increase the risk of cataracts. If fai lure to comply 
with eye protection were more frequent in patients who received 
lower exposures to PUV A and such unprotected exposure was the 
principal risk factor for the development of lenticular changes in 
association with the use of PUV A therapy, increases in risk of lens 
damage associated with unprotected eye exposure would not be 
apparent from our analysis. Also, our data cannot exclude the possi-
bility that even low levels of exposure to PUV A damage the ocular 
lens, but the extent of damage does not increase with increased 
exposure to PUV A. 
Our study is based on more than 13,000 person-years of prospec-
t ive data. Multiple trained examiners (usually ophthalmologists, but 
some optometrists) completed these examinations. We did, how-
ever, encourage individual patients to return to the same eye physi-
cian as much as possible. 
We are concerned that varying patient compliance with the use 
of protective eye glasses might mask a dose-dependent relationship 
between the development of an eye abnorma li ty and exposure to 
PUVA. Our data do not, however, demonstrate any dose-dependent 
increase in the risk of the development of lenticular abnormalities 
with PUV A. Because of our lack of data on compliance and the 
observed higher prevalence of some abnormalities compared to 
1.1 
1.4 
0.7 -1.6 
0.9 -2.0 
1 
1.2 
0.9 
0.8 
1 
0.8-1.7 
0.6-1.3 
0.5-1.1 
population studies, we continue to believe that it is necessary that 
patients receiving PUV A therapy continue to wear adequate eye 
protection for at least 12 h after psoralen ingestion, and we cannot 
exclude the possibility that even limited exposure to PUV A might 
increase the risk of lens abnormalities. 
This work was sllpported i,1 part by the Natiollallt,st iwte of Arthrit is, Mllswloskel-
cta l, (/lid Skill Diseases, COlltract 1-AM-2252. 
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